EdgarLookup

Red Cat Holdings, Inc. — Financial Data

Annual figures from SEC EDGAR XBRL filings (10-K)

These figures are extracted directly from XBRL-tagged financial statements that Red Cat Holdings, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.

Overview All Filings Annual Quarterly Insiders
-404.1%
Profit Margin
Net income ÷ revenue
-26.3%
Return on Assets
Net income ÷ assets
0.11x
Debt-to-Equity
Total liabilities ÷ equity
+286%
Revenue Growth
Year over year

Revenue

Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.

Fiscal Year Period End Value Filed
FY2024 Apr 30, 2024 $17.84M Aug 8, 2024
FY2024 Apr 30, 2023 $4.62M Aug 8, 2024
FY2023 Apr 30, 2022 $6.43M Jul 27, 2023
FY2022 Apr 30, 2021 $5.00M Aug 15, 2022
FY2021 Apr 30, 2020 $403.9K Aug 12, 2021
FY2018 Dec 31, 2018 $105.1K Apr 1, 2019
FY2017 Dec 31, 2017 $933 Apr 9, 2018
FY2017 Dec 31, 2016 $203.6K Apr 9, 2018
FY2015 Dec 31, 2015 $59.4K Apr 13, 2016
FY2015 Dec 31, 2014 $42.1K Apr 13, 2016

Revenue

Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $40.73M Mar 19, 2026
FY2025 Dec 31, 2024 $4.85M Mar 19, 2026
FY2025 Apr 30, 2024 $17.84M Mar 19, 2026
FY2024 Apr 30, 2023 $1.31M Aug 8, 2024

Gross Profit

Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $1.27M Mar 19, 2026
FY2025 Dec 31, 2024 ($1.36M) Mar 19, 2026
FY2025 Apr 30, 2024 $3.68M Mar 19, 2026
FY2024 Apr 30, 2023 ($834.3K) Aug 8, 2024
FY2023 Apr 30, 2022 $925.5K Jul 27, 2023
FY2022 Apr 30, 2021 $1.07M Aug 15, 2022
FY2021 Apr 30, 2020 $78.6K Aug 12, 2021
FY2018 Dec 31, 2018 ($246.7K) Apr 1, 2019
FY2017 Dec 31, 2017 $653 Apr 9, 2018
FY2017 Dec 31, 2016 $203.6K Apr 9, 2018

Net Income

The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 ($72.08M) Mar 19, 2026
FY2025 Dec 31, 2024 ($43.61M) Mar 19, 2026
FY2025 Apr 30, 2024 ($24.05M) Mar 19, 2026
FY2024 Apr 30, 2023 ($28.11M) Aug 8, 2024
FY2023 Apr 30, 2022 ($11.69M) Jul 27, 2023
FY2022 Apr 30, 2021 ($13.24M) Aug 15, 2022
FY2021 Apr 30, 2020 ($1.60M) Aug 12, 2021
FY2020 Apr 30, 2019 ($751.3K) Aug 13, 2020
FY2018 Dec 31, 2018 ($2.64M) Apr 1, 2019
FY2018 Dec 31, 2017 $1.13M Apr 1, 2019

Operating Income

Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 ($66.60M) Mar 19, 2026
FY2025 Dec 31, 2024 ($25.84M) Mar 19, 2026
FY2025 Apr 30, 2024 ($19.30M) Mar 19, 2026
FY2024 Apr 30, 2023 ($26.38M) Aug 8, 2024
FY2020 Apr 30, 2020 ($1.66M) Aug 13, 2020
FY2020 Apr 30, 2019 ($751.3K) Aug 13, 2020
FY2018 Dec 31, 2018 ($2.08M) Apr 1, 2019
FY2018 Dec 31, 2017 ($1.09M) Apr 1, 2019
FY2017 Dec 31, 2016 ($1.45M) Apr 9, 2018
FY2015 Dec 31, 2015 ($239.0K) Apr 13, 2016

R&D Expense

Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $17.89M Mar 19, 2026
FY2025 Dec 31, 2024 $6.61M Mar 19, 2026
FY2025 Apr 30, 2024 $6.27M Mar 19, 2026
FY2024 Apr 30, 2023 $5.60M Aug 8, 2024
FY2023 Apr 30, 2022 $2.61M Jul 27, 2023
FY2022 Apr 30, 2021 $516.1K Aug 15, 2022
FY2021 Apr 30, 2020 $489.0K Aug 12, 2021
FY2020 Apr 30, 2019 $366.6K Aug 13, 2020
FY2017 Dec 31, 2017 $993.9K Apr 9, 2018
FY2017 Dec 31, 2016 $860.5K Apr 9, 2018

SG&A Expense

Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.

Fiscal Year Period End Value Filed
FY2012 Dec 31, 2012 $230.4K Mar 28, 2013
FY2012 Dec 31, 2011 $53.8K Mar 28, 2013

Operating Cash Flow

Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.

Fiscal Year Period End Value Filed
FY2023 Apr 30, 2023 ($29.20M) Jul 27, 2023
FY2023 Apr 30, 2022 ($16.02M) Jul 27, 2023
FY2022 Apr 30, 2021 ($1.40M) Aug 15, 2022
FY2021 Apr 30, 2020 ($811.6K) Aug 12, 2021
FY2020 Apr 30, 2019 ($753.4K) Aug 13, 2020
FY2018 Dec 31, 2018 ($943.6K) Apr 1, 2019
FY2018 Dec 31, 2017 ($1.44M) Apr 1, 2019
FY2017 Dec 31, 2016 ($1.59M) Apr 9, 2018
FY2015 Dec 31, 2015 ($112.5K) Apr 13, 2016
FY2015 Dec 31, 2014 ($216.7K) Apr 13, 2016

Capital Expenditures (Capex)

Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.

Fiscal Year Period End Value Filed
FY2015 Dec 31, 2015 $0 Apr 13, 2016
FY2015 Dec 31, 2014 $0 Apr 13, 2016

Total Assets

The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $273.68M Mar 19, 2026
FY2025 Dec 31, 2024 $55.60M Mar 19, 2026
FY2024 Apr 30, 2024 $48.54M Aug 8, 2024
FY2024 Apr 30, 2023 $60.74M Aug 8, 2024
FY2023 Apr 30, 2022 $85.08M Jul 27, 2023
FY2022 Apr 30, 2021 $11.69M Aug 15, 2022
FY2021 Apr 30, 2020 $2.81M Aug 12, 2021
FY2020 Apr 30, 2019 $603.4K Aug 13, 2020
FY2018 Dec 31, 2018 $262.4K Apr 1, 2019
FY2018 Dec 31, 2017 $750.2K Apr 1, 2019

Total Liabilities

All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $27.85M Mar 19, 2026
FY2025 Dec 31, 2024 $5.49M Mar 19, 2026
FY2018 Dec 31, 2018 $2.77M Apr 1, 2019
FY2018 Dec 31, 2017 $2.61M Apr 1, 2019
FY2017 Dec 31, 2016 $4.43M Apr 9, 2018
FY2015 Dec 31, 2015 $312.7K Apr 13, 2016
FY2015 Dec 31, 2014 $308.6K Apr 13, 2016
FY2014 Dec 31, 2013 $27.7K Mar 31, 2015
FY2013 Dec 31, 2012 $98.7K Mar 17, 2014
FY2012 Dec 31, 2011 $1.08M Mar 28, 2013

Stockholders Equity

The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $245.83M Mar 19, 2026
FY2025 Dec 31, 2024 $50.12M Mar 19, 2026
FY2025 Apr 30, 2024 $43.56M Mar 19, 2026
FY2025 Apr 30, 2023 $54.77M Mar 19, 2026
FY2024 Apr 30, 2022 $79.09M Aug 8, 2024
FY2023 Apr 30, 2021 $5.27M Jul 27, 2023
FY2022 Apr 30, 2020 $1.53M Aug 15, 2022
FY2021 Apr 30, 2019 ($187.3K) Aug 12, 2021
FY2018 Dec 31, 2018 ($2.51M) Apr 1, 2019
FY2020 Apr 30, 2018 $514.1K Aug 13, 2020

Goodwill

An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $17.67M Mar 19, 2026
FY2025 Dec 31, 2024 $17.67M Mar 19, 2026
FY2024 Apr 30, 2024 $9.09M Aug 8, 2024
FY2024 Apr 30, 2023 $17.01M Aug 8, 2024
FY2023 Apr 30, 2022 $25.14M Jul 27, 2023
FY2022 Apr 30, 2021 $8.02M Aug 15, 2022
FY2021 Apr 30, 2020 $2.47M Aug 12, 2021
FY2015 Dec 31, 2015 $0 Apr 13, 2016
FY2015 Dec 31, 2014 $256.0K Apr 13, 2016
FY2014 Dec 31, 2013 $0 Mar 31, 2015

Retained Earnings

Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 ($196.82M) Mar 19, 2026
FY2025 Dec 31, 2024 ($124.75M) Mar 19, 2026
FY2024 Apr 30, 2024 ($81.13M) Aug 8, 2024
FY2024 Apr 30, 2023 ($57.08M) Aug 8, 2024
FY2023 Apr 30, 2022 ($27.50M) Jul 27, 2023
FY2022 Apr 30, 2021 ($15.81M) Aug 15, 2022
FY2021 Apr 30, 2020 ($2.57M) Aug 12, 2021
FY2020 Apr 30, 2019 ($971.8K) Aug 13, 2020
FY2018 Dec 31, 2018 ($5.38M) Apr 1, 2019
FY2018 Dec 31, 2017 ($2.74M) Apr 1, 2019

Cash & Equivalents

Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.

Fiscal Year Period End Value Filed
FY2018 Dec 31, 2018 $5.8K Apr 1, 2019
FY2018 Dec 31, 2017 $559.2K Apr 1, 2019
FY2018 Dec 31, 2016 $225.4K Apr 1, 2019
FY2017 Dec 31, 2015 $3.2K Apr 9, 2018
FY2013 Dec 31, 2013 $7.0K Mar 17, 2014
FY2013 Dec 31, 2012 $94.6K Mar 17, 2014
FY2013 Dec 31, 2011 $12.0K Mar 17, 2014

Long-Term Debt

Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.

Fiscal Year Period End Value Filed
FY2013 Dec 31, 2013 $0 Mar 17, 2014
FY2013 Dec 31, 2012 $0 Mar 17, 2014
FY2012 Dec 31, 2011 $0 Mar 28, 2013

EPS (Basic)

Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 0 Mar 19, 2026
FY2025 Dec 31, 2024 0 Mar 19, 2026
FY2025 Apr 30, 2024 0 Mar 19, 2026
FY2018 Dec 31, 2018 0 Apr 1, 2019
FY2018 Dec 31, 2017 0 Apr 1, 2019
FY2017 Dec 31, 2016 0 Apr 9, 2018
FY2015 Dec 31, 2015 0 Apr 13, 2016
FY2015 Dec 31, 2014 (6) Apr 13, 2016
FY2014 Dec 31, 2013 0 Mar 31, 2015
FY2013 Dec 31, 2012 0 Mar 17, 2014

EPS (Diluted)

Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 0 Mar 19, 2026
FY2025 Dec 31, 2024 0 Mar 19, 2026
FY2025 Apr 30, 2024 0 Mar 19, 2026
FY2018 Dec 31, 2018 0 Apr 1, 2019
FY2018 Dec 31, 2017 0 Apr 1, 2019
FY2017 Dec 31, 2016 0 Apr 9, 2018
FY2015 Dec 31, 2015 0 Apr 13, 2016
FY2015 Dec 31, 2014 (2) Apr 13, 2016
FY2014 Dec 31, 2013 0 Mar 31, 2015

Shares Outstanding

Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 120.07M Mar 19, 2026
FY2025 Dec 31, 2024 85.22M Mar 19, 2026
FY2025 Apr 30, 2024 74.29M Mar 19, 2026
FY2024 Apr 30, 2023 54.57M Aug 8, 2024
FY2023 Apr 30, 2022 53.75M Jul 27, 2023
FY2022 Apr 30, 2021 29.43M Aug 15, 2022
FY2021 Apr 30, 2020 20.01M Aug 12, 2021
FY2020 Apr 30, 2019 179,292 Aug 13, 2020
FY2018 Dec 31, 2018 235.46M Apr 1, 2019
FY2018 Dec 31, 2017 47.27M Apr 1, 2019